Obsidian Therapeutics is a biotechnology company developing next-generation cell and gene therapies with pharmacologic operating systems. Based upon founding work on destabilizing domains by Professor Thomas Wandless, a leading researcher in chemical and systems biology, Obsidian's lead programs are CAR-T products that incorporate controllable functions for enhanced safety and efficacy. Obsidian was founded in 2015 by Atlas Venture and is funded by a strong syndicate of venture investors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/06/17 | $49,500,000 | Series A |
Alexandria Real Estate Equities Amgen Business Development Atlas Venture ShangPharma Investment Group Takeda Ventures Vertex Ventures | undisclosed |
| 04/03/24 | $160,500,000 | Series C |
Atlas Venture Blue Owl Bristol Myers Squibb Deep Track Capital Foresite Capital Janus Henderson Investors Logos Capital Novo Holdings Paradigm BioCapital RA Capital Management RTW Investments Samsara BioCapital Surveyor Capital TCGX Wellington Management  Woodline Partners | undisclosed |
